8-K: LifeMD Reports First Quarter 2025 Results, Raises Full-Year Guidance Amidst Telehealth Surge

LifeMD announces a strong first quarter in 2025, marked by a 49% increase in total revenue and its first-ever quarter of positive GAAP EPS, leading to raised full-year guidance.

Summary

• LifeMD reported its financial results for the three months ended March 31, 2025.
• Total revenues increased by 49% year-over-year to $65.7 million.
• Telehealth revenue saw a significant increase of 70%.
• Adjusted EBITDA increased to $8.7 million, a substantial improvement from $0.1 million in the same period last year.
• The telehealth segment's adjusted EBITDA improved to $5.3 million from a loss of $1.3 million year-over-year.
• LifeMD achieved its first-ever quarter of positive GAAP net income, reporting $0.6 million or $0.01 per diluted share.
• The company is raising its full-year 2025 guidance for total revenues to a range of $268 million to $275 million.
• Adjusted EBITDA guidance for the full year is also raised to a range of $31 million to $33 million.
• For the second quarter of 2025, the company expects total revenues between $65 million and $67 million, and adjusted EBITDA between $7 million and $9 million.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, raised guidance, and strategic expansions, indicating a favorable sentiment.

Positives

• Significant revenue growth, with total revenues up 49% and telehealth revenue up 70%.
• Substantial improvement in profitability, achieving positive GAAP net income for the first time.
• Strong growth in adjusted EBITDA, both overall and within the telehealth segment.
• Increase in telehealth active subscribers by 22%.
• Raised full-year guidance for both total revenues and adjusted EBITDA.
• Strategic collaborations with LillyDirect and NovoCare are generating momentum.
• Expansion into mental and hormonal health verticals through key hires and acquisitions.

Negatives

• Gross margin decreased slightly from 90% to 87% due to revenue mix and the launch of LifeMD's pharmacy.
• WorkSimpli revenue remained flat with 0% growth year-over-year.
• WorkSimpli active subscribers decreased by 5%.

Risks

• The cautionary note regarding forward-looking statements highlights inherent risks and uncertainties that could cause actual results to differ materially.
• These risks include factors identified in the company's filings with the SEC, such as the most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
• The company's future performance is subject to market conditions, regulatory developments, and the ability to comply with evolving regulations.

Future Outlook

LifeMD is raising its full-year 2025 guidance, now expecting total revenues in the range of $268 million to $275 million and adjusted EBITDA in the range of $31 million to $33 million.

Management Comments

• Justin Schreiber, Chairman and CEO of LifeMD, stated that LifeMD had an outstanding first quarter, demonstrating the power of their platform and the accelerated growth trajectory of the business.
• Marc Benathen, Chief Financial Officer of LifeMD, commented that they achieved positive GAAP net income for the first time and are raising full-year 2025 guidance to reflect their strong performance to date.

Industry Context

LifeMD's focus on telehealth and virtual primary care aligns with the growing trend of digital health solutions. The collaborations with LillyDirect and NovoCare to offer GLP-1 medications position LifeMD competitively in the weight management space.

Comparison to Industry Standards

• Teladoc Health, a major player in the telehealth industry, reported Q1 2024 revenue of $629.2 million, showcasing the scale of larger, more established companies.
• Amwell, another telehealth provider, reported Q1 2024 revenue of $69.2 million, putting LifeMD's $65.7 million in a similar range for revenue generation.
• Companies like Hims & Hers Health, Inc. focus on specific telehealth niches, similar to LifeMD's expansion into mental and hormonal health, demonstrating a trend towards specialization.
• The adjusted EBITDA margins for LifeMD are improving, but still need to be compared to industry benchmarks to assess long-term sustainability.

Legal Proceedings

• The company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company's Form 10-Q for the three months ended March 31, 2025, filed on May 6, 2025.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a broader range of telehealth services and convenient access to medications through strategic collaborations.

Next Steps

• LifeMD's management will host a conference call to discuss the company's financial results and outlook.
• The company will continue to focus on expanding its telehealth platform and strategic collaborations.
• LifeMD will integrate newly acquired assets in behavioral health and women's health.

Key Dates

Keywords

LifeMD, telehealth, revenue, EBITDA, financial results, guidance, virtual primary care, healthcare